|
co.don AG - Excellent results of GCP-study EuroDISC on ADCT treatment of disc herniation and low back pain |
|
|
|
16 Aug 2006 |
A new interim analysis of the GCP-study EuroDISC on the ADCT treatment of disc herniation and low back pain using the autologous disc-derived cell transplant co.don chondrotransplantâ DISC shows the clear therapeutic benefit of ADCT as compared to the standard surgical treatment: The low back pain and the disability index have been progressively reduced by 70% to 30% in the ADCT-treated patients in comparison to the control group.
TELTOW, Germany | Aug 15, 2006 | A new interim analysis of the GCP-study EuroDISC on the ADCT treatment of disc herniation and low back pain using the autologous disc-derived cell transplant co.don chondrotransplantâ DISC shows the clear therapeutic benefit of ADCT as compared to the standard surgical treatment: The low back pain and the disability index have been progressively reduced by 70% to 30% in the ADCT-treated patients in comparison to the control group.
Teltow, August 15, 2006 – co.don AG (WKN 517360) – The statistical analysis of a subgroup of 52 randomised and treated patients within the scope of the study showed a clear decrease of the back pain and a distinct reduction of the disability index in the ADCT-treated patients in comparison to the control group, in the period up to 24 months after successful ADCT or control check-ups.
Already one year after the treatment, a twofold clinical superiority of the ADCT in comparison to the control group could be proved. Moreover, within the two-year period following the treatment, the content of fluid in the affected and adjacent intervertebral disc of the control group was notably lower than in the ADCT group. These results show that the ADCT treatment decreases the loss of the content of fluid in the both affected as well as adjacent intervertebral disc. Decrease of fluid content is considered to be a sign of a progressive disc degeneration.
The ADCT treatment includes the transplantation of the autologous cultured intervertebral disc-derived chondrocytes, co.don chondrotransplantâ DISC, after the surgical removal of the disc herniation. co.don chondrotransplantâ DISC is an innovative human Tissue engineering therapeutic indicated for the biological repair of degenerated intervertebral disc, i.e. for biological nucleus replacement.
The clinical study EuroDISC of co.don AG is worldwide the first prospective, controlled, randomized, multi-centric clinical study on the biological repair of degenerated intervertebral disc using autologous cultured disc-derived chondrocytes. The aim of the ADCT is to prevent the spontaneous height loss of the intervertebral disc often accompanied by persistent and strong low back pain.
The market for orthopedic biomaterials in the U.S. amounts to approx. US $ 1.4 billion with an annual growth rate of 20%. Market potential in Europe is about US $ 230 million with an annual growth rate
of 60%.
The Board of Management
Contact:
Matthias Meißner
Tel. +49 (0)3328-434630
Fax +49 (0)3328-434649
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
co.don® AG is one of the leading biopharmaceutical companies in the area of Regenerative Medicine/Tissue Engineering. Since 1997, co.don® AG has developed, manufactured and distributed human Tissue engineering therapeutics for the regeneration of articular cartilage, bone and intervertebral discs.
The company is headquartered in Teltow near Berlin, Germany. For more information, please visit www.codon.de
SOURCE: co.don® AG |
